International AIDS Society

From Wikipedia, the free encyclopedia
  (Redirected from AIDS advocacy)
Jump to navigation Jump to search
International AIDS Society
Founded1988; 33 years ago (1988)
Stockholm, Sweden
Key people
Number of employees
52 [1] (2016)

The International AIDS Society (IAS) is the world's largest association of HIV/AIDS professionals, with 11,600 members from over 170 countries as of July 2020, including clinicians, people living with HIV, service providers, policy makers and others. It aims to reduce the global impact of AIDS through collective advocacy. Founded in 1988, IAS headquarters are located in Geneva, and its president since July 2020 is Adeeba Kamarulzaman.

The IAS hosts the biennial International AIDS Conference, the IAS Conference on HIV Science, and the HIV Research for Prevention Conference.


The IAS is a non-profit organization founded in 1988, with a mandate to organize the International AIDS Conference. Initially, the IAS headquarters were in Stockholm, and Lars-Olof Kallings was the secretary general from 1988 until 2003.

In 2004, the IAS restructured its organization, expanded the number of professional staff and moved the headquarters to Geneva. The move was intended to strengthen organizational links with other health NGOs and (United Nations) multilateral agencies.

Mission and Office-bearers[edit]

The IAS is an advocacy body, using its large membership base and scientific leadership to drive action. It is the world’s largest association of HIV professionals, with 11,600 members from over 170 countries as of July 2020. Among its members are researchers, clinicians, people living with HIV, community advocates, policy makers and others.[2]

The IAS President as of July 2020 is Adeeba Kamarulzaman of Malaysia,[3] who succeeds Anton Pozniak. Kevin Osborne is Executive Director.[2] Past presidents have included Helene D. Gayle, Joep Lange, Peter Piot, Linda-Gail Bekker, Chris Beyrer and Françoise Barré-Sinoussi.[4]


International AIDS Conference[edit]

The International AIDS Conference (abbreviated AIDS 2012, AIDS 2014 and so on) is the world's most attended conference on HIV and AIDS, and the largest conference on any global health or development issue in the world.[5] First convened during the peak of the AIDS epidemic in 1985, they were held annually until 1994 when they became biennial. Each conference continues to provide a unique forum for the intersection of science, advocacy and human rights, as well as to strengthen policies and programmes that ensure an evidence-based response to the epidemic.

The 2006 World Aids Conference was held in Toronto, Canada.[6]

The 22nd International AIDS Conference (AIDS 2018) was held in Amsterdam, the Netherlands, on 21-27 July 2018.[7] Primary topics of note included: Use of Dolutegravir as an antiretroviral medication was reported to result in increased rates of birth defects where the brain and spinal cord have openings - Neural tube defects.[8] Particularly of note was that an HIV infected person on treatment with undetectable virus does not spread it to an uninfected partner.[9]

The 23rd International AIDS Conference (AIDS 2020) will be held in San Francisco and Oakland, United States, on 6–10 July 2020.

IAS Conference on HIV Science[edit]

The IAS also organizes the IAS Conference on HIV Science (abbreviated IAS 2013, IAS 2015 and so on) (formerly called the IAS Conference on HIV Pathogenesis, Treatment and Prevention). This conference, the largest open scientific conference on HIV- and AIDS-related issues, occurs biennially and focuses on the biomedical aspects of HIV. The conference brings together professionals from around the world to examine the latest scientific developments in HIV research, prevention and treatment with a focus on moving science into practice and policy. It was held in Buenos Aires in 2001, Paris in 2003, Rio de Janeiro in 2005, Sydney in 2007, Cape Town in 2009, Rome in 2011, Kuala Lumpur in 2013, Vancouver in 2015 and Paris in 2017. IAS 2019 will be held in Mexico City, Mexico on 21–24 July 2019.

The conference was called the IAS Conference on HIV Pathogenesis, Treatment and Prevention until a name change after 2015.

Publications and other resources[edit]

The society financially supports the publication of the Journal of the International AIDS Society (JIAS), an online, open-access, peer-reviewed medical journal covering all aspects of research on HIV and AIDS.

The IAS Online Resource Library is an online collection of abstracts and other resources from international conferences, as well as numerous other materials produced by the IAS launched in January 2010.

Other activities[edit]

The IAS works with other regional HIV/AIDS societies and networks to strengthen the capacity of HIV professionals to respond to the epidemic at the regional level. The society runs the Industry Liaison Forum, whose mission is to remove barriers to research investment by the pharmaceutical industry in resource-limited settings. The IAS also provides professional development and training opportunities for HIV professionals at both international and regional AIDS conferences through its education programme.


  1. ^ "Annual Report July 2016-2017". International AIDS Society. Retrieved 20 March 2018.
  2. ^ a b "International AIDS Society Annual Report 2019-2020" (PDF). International AIDS Society. July 2020. Cite journal requires |journal= (help)
  3. ^ "Adeeba Kamarulzaman of Malaysia announced as the first Asian President of IAS – the International AIDS Society". iasociety. Retrieved 21 October 2020.
  4. ^ "Looking back with the IAS presidents [1998–2016]". IAS. Retrieved 21 October 2020.
  5. ^ 2008 UNAIDS Annual Report, p.13, WHO
  6. ^ Gayle, Helene; Wainberg, Mark A (19 April 2007). "The 16th International Conference on AIDS: Will It Leave a Legacy?". Journal of the International AIDS Society. 9: 15. doi:10.1186/1758-2652-9-2-15. PMC 2758903.
  7. ^ "AIDS 2018 opens in Amsterdam with focus on putting HIV response back on track - Xinhua |". Retrieved 2018-07-24.
  8. ^ Zash, Rebecca; Makhema, Joseph; Shapiro, Roger L. (2018). "Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception". New England Journal of Medicine. 379 (10): 979–981. doi:10.1056/NEJMc1807653. ISSN 0028-4793. PMC 6550482. PMID 30037297.
  9. ^ "HIV-positive people with undetectable viral loads cannot transmit the disease, study shows". Retrieved 2018-07-24.

External links[edit]